Altamira Therapeutics Ltd Stock Price, News & Analysis

Altamira Therapeutics (NASDAQ:CYTO) announced reaching the enrollment midpoint in its COVAMID trial of Bentrio nasal spray for acute COVID-19. The trial aims to evaluate Bentrio's effectiveness in reducing SARS-CoV-2 viral load, alleviating symptoms, and decreasing hospital admissions. A total of 136 COVID-19 patients will participate in a randomized study. Positive in vitro results have already been observed, with plans to expand the trial to North Macedonia and possibly India. Completion is anticipated by Q3 2022.

Altamira Therapeutics (NASDAQ:CYTO) announced key developments during its investor call on April 12, 2022. The company is pivoting towards RNA therapeutics with its OligoPhore and SemaPhore platforms, having made significant progress, including the completion of enrollment in the Bentrio house dust mite trial and the launch of a clinical trial for acute COVID-19. Financially, Altamira reported a net loss of CHF 17.4 million for 2021, while revenues reached CHF 0.1 million. The company has plans to divest its legacy business and enhance its RNA capabilities, aiming for an FDA IND in 2023.

Altamira Therapeutics (NASDAQ: CYTO) announced the publication of a study in the International Journal of Molecular Sciences confirming the efficacy and safety of its drug-free nasal spray, Bentrio, against the SARS-CoV-2 Delta variant. The study demonstrated a reduction in viral titer by up to 99% and highlighted Bentrio's potential as a prophylactic treatment. The company is also conducting a COVAMID clinical trial for acute COVID-19 patients. Bentrio is already available in parts of Europe and aims for broader distribution.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a conference call for April 12, 2022, at 8:00 a.m. ET to discuss its full-year 2021 earnings. The session will be accessible via teleconference or webcast, including audio and presenter-controlled slides. The company focuses on developing therapeutics addressing unmet medical needs across various platforms, including RNA therapeutics and nasal sprays. The replay of the call will be available for two weeks following the initial event.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has completed patient enrollment in its Bentrio™ trial for house dust mite (HDM) allergic rhinitis, involving 37 patients. The trial aims to assess Bentrio's efficacy in treating perennial allergic rhinitis under controlled HDM exposure, with top-line results expected in Q2 2022. The company's CEO emphasized the importance of Bentrio, following positive outcomes in previous studies. Notably, HDM allergies affect millions globally and can severely impact quality of life.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced promising in vitro results for its Bentrio™ nasal spray against the Omicron variant of SARS-CoV-2. The study showed that prophylactic use of Bentrio prior to viral exposure reduced viral titer by 89.5% within 24 hours, compared to saline controls. Even when applied after peak viral levels, significant reductions of 87.1%COVAMID, is underway to further evaluate Bentrio's efficacy in COVID-19 patients.

Altamira Therapeutics (NASDAQ:CYTO) has received approval to initiate the COVAMID clinical trial evaluating Bentrio™ as a treatment for COVID-19. The study will involve 136 confirmed cases, randomized into groups receiving Bentrio™, placebo, or no treatment, over a 10-day period. Based on interim analysis, participants may increase to 180. Bentrio™ aims to reduce SARS-CoV-2 viral load and alleviate symptoms. Earlier studies indicated over a 99% viral load reduction with Bentrio™. The trial will begin in Bulgaria, with potential expansion to two other countries.

Altamira Therapeutics (NASDAQ:CYTO) has secured an exclusive licensing agreement with Nuance Pharma for its nasal spray, Bentrio™, targeting the Chinese Mainland, Hong Kong, Macau, and South Korea. This deal includes a $1 million upfront payment, with potential milestone payments up to $23.5 million. Nuance will manage local production and will pay royalties based on net sales once production starts. The collaboration aims to address the significant market need for allergy and virus protection, especially given the prevalence of allergic rhinitis affecting 246 million in the region.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has completed patient enrollment in Part B of the Phase 2 'TRAVERS' clinical trial for AM-125, an intranasal formulation of betahistine aimed at treating acute vertigo. This trial involves 75 patients and seeks to demonstrate efficacy through the Tandem Romberg test. Following positive interim results from Part A, the company anticipates announcing top-line results by Q2 2022. AM-125 offers higher bioavailability than oral betahistine and addresses a significant medical need affecting many U.S. adults over 40.